Form 4: Black Diamond Therapeutics Director Acquires Shares in Lieu of Cash Compensation

Director Wendy L. Dixon acquired 3,253 shares of Black Diamond Therapeutics common stock in lieu of cash compensation for annual services as a non-employee director.

Summary

• On March 15, 2024, Wendy L. Dixon, a director of Black Diamond Therapeutics, Inc., acquired 3,253 shares of common stock.
• The shares were issued in accordance with the Issuer's Fifth Amended and Restated Non-Employee Director Compensation Policy.
• Dixon elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director.
• The price of the stock was $4.54 per share, based on the closing market price on March 14, 2024.
• Following the transaction, Dixon beneficially owns 38,054 shares of Black Diamond Therapeutics common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral. A director taking stock in lieu of cash is generally a positive sign, but it's a standard compensation practice.

Positives

• A director's decision to take shares in lieu of cash compensation can be seen as a positive sign of confidence in the company's future.

Industry Context

This type of transaction, where directors receive stock in lieu of cash, is a fairly common practice in the biotech industry, especially for smaller companies looking to conserve cash.

Comparison to Industry Standards

• Director compensation packages vary widely across the biotech industry.
• Some companies offer a mix of cash and stock options, while others rely more heavily on equity-based compensation to align director interests with shareholder value.
• Comparing Black Diamond Therapeutics' director compensation policy to those of similar-sized biotech companies would provide a better understanding of its competitiveness.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it aligns director interests with the company's stock performance.

Key Dates